S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen

Inclusion Criteria: * Cytologically or histologically confirmed evidence of adenocarcinoma of the exocrine pancreas * Metastatic disease previously treated with a gemcitabine-based regimen Exclusion Criteria: * Locally advanced disease * More than one prior chemotherapy-line for advanced pancreatic disease * Prior treatment with fluoropyrimidines for advanced pancreatic cancer * Eastern Cooperative Oncology Group (ECOG) performance status \>or= 2 * Poor kidney, liver or bone marrow functions * Any serious active disease or co-morbid condition, which in the opinion of the principle investigator, will interfere with the safety or with compliance with the study * Unable to swallow capsules * Hypersensitivity history to any of the constituents of the study medications or fluoropyrimidines * Concurrent participation in another clinical trial or treatment with any other anticancer therapy The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.